Redhill Biopharma's RHB-102: A Promising GI Treatment for GLP-1/GIP Receptor Agonist Therapy-Associated GI Side Effects

Redhill Biopharma's stock is trading lower on Tuesday, possibly due to profit-taking after a 36% rally on Monday. The company announced development progress for RHB-102, a once-daily oral ondansetron therapy for GI side effects associated with GLP-1/GIP receptor agonist therapy. RHB-102 has the potential to improve titration success and reduce early discontinuation of GLP-1/GIP-based diabetes and weight loss therapies. The stock is currently down 4.29% at $1.34.